Phase II Study Results Showed Comparable Viral Suppression Rates at 96 Weeks for a Two-Drug Regimen...
Phase II Study Results Showed Comparable Viral Suppression Rates at 96 Weeks for a Two-Drug Regimen of Long-Acting Cabotegravir and Rilpivirine and a Three-Drug Regimen in Patients With HIV
About this item
Full title
Phase II Study Results Showed Comparable Viral Suppression Rates at 96 Weeks for a Two-Drug Regimen of Long-Acting Cabotegravir and Rilpivirine and a Three-Drug Regimen in Patients With HIV
Publisher
Washington, D.C: Targeted News Service
Journal title
Targeted News Service, 2017
Language
English
Formats
Publication information
Publisher
Washington, D.C: Targeted News Service
Subjects
More information
Alternative Titles
Full title
Phase II Study Results Showed Comparable Viral Suppression Rates at 96 Weeks for a Two-Drug Regimen of Long-Acting Cabotegravir and Rilpivirine and a Three-Drug Regimen in Patients With HIV
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_1922893760
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_1922893760
How to access this item
Log in as a Library member
